About: NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.42 (+10.94%)
NRSN NASDAQ Neurosense Therapeutics Ltd
Neurosense Therapeutics Ltd share price
NRSN price activity
Last Price
$1.420
Change (24hr)
0.14 USD (10.94%)
Volume
23.07K
Volume (4w avg)
-
Open
$1.33
Day Range
$1.31 - $1.45
Previous Close
$1.28
Last Trade
04 Nov, 9:00 pm GMT+0
Delayed
04 Nov, 9:00 pm GMT+0
NRSN price performance
Delayed
04 Nov, 9:00 pm GMT+0
NRSN details
NRSN Market Signals